ABSTRACT
Introduction COVID-19 pandemic has modified the epidemiology of lower respiratory tract infections (LRTI), particularly in patients presenting a chronic respiratory disease (CRD). LRTI incidence substantially decreased at the start of the COVID-19 pandemic. However, studies focusing on the post-pandemic period are missing. We aimed to evaluate the impact of the pandemic and post-pandemic periods on hospital admissions for LRTI, with a focus on patients with CRD.
Methods From July 2013 to June 2023, monthly numbers of adult hospitalisations for LRTI (excluding SARS-CoV-2) were extracted from the anonymized French National Hospital Discharge Database. They were modelled by regressions with autocorrelated errors. Three periods were defined: (1) early pandemic and successive lockdowns (April 2020 to May 2021); (2) gradual lifting of restrictions and widespread SARS-CoV-2 vaccination (June 2021 to June 2022); (3) withdrawal of restriction measures (July 2022 to July 2023). Analyses were computed for the entire series, by gender, age, severity, and pre-existing CRD
Results Before the pandemic, LRTI hospitalisations showed a winter seasonal pattern with a rising trend. Pre-pandemic incidence was 96 (90.5 to 101.5) per 100,000 population. Compared with the pre-pandemic period, seasonality was no longer present and significant reductions were estimated in the first two periods: −43.64% (−50.11 to −37.17) and −32.97% (−39.88 to −26.05), respectively. A rebound with a positive trend and a seasonal pattern was observed in period 3. Similar results were observed for CRD patients with no significant difference with pre-pandemic levels in the last period (−9.21%; −20.9% to 1.67%), albeit with differential changes according to the type of CRD.
Conclusions COVID-19 pandemic containment measures contributed to significant changes in LRTI incidence, with a rapid increase and return to a seasonal pattern after their gradual lifting, particularly in patients with CRD.
Competing Interest Statement
ASE reports support for attending meeting from SOS Oxygene and LVL Medical outside the submitted work. MF reports grants from BioMerieux and personal fees from BioMerieux, Pfizer, SOS Oxygene and Fisher and Paykel outside the submitted work. LW reports personal fees from Pfizer, Sanofi and Heva outside the submitted work. DG, CBB and LB have no competing interests to declare.
Funding Statement
Doctoral fellowship was received by AES from Paris-Saclay University. The funder has no role in the conceptualization, design, data collection, analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted using the Institut National de la Sante et de la Recherche Medicale permanent access to the the French National Hospital Discharge Database.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Aggregated monthly data were used for the time series analysis and are available from the corresponding author on reasonable request. The pseudonymized data extracted from the PMSI are only accessible to accredited structures and can be accessed with the permission from the Agence Technique de l Information sur l Hospitalisation
